Institution
Chinese Center for Disease Control and Prevention
Government•Beijing, China•
About: Chinese Center for Disease Control and Prevention is a government organization based out in Beijing, China. It is known for research contribution in the topics: Population & Acquired immunodeficiency syndrome (AIDS). The organization has 16037 authors who have published 15098 publications receiving 423452 citations. The organization is also known as: China CDC & CCDC.
Topics: Population, Acquired immunodeficiency syndrome (AIDS), Virus, Vaccination, Men who have sex with men
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.
Abstract: High blood cholesterol is typically considered a feature of wealthy western countries1,2. However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world3 and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health4,5. However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol—which is a marker of cardiovascular risk—changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million–4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.
86 citations
••
TL;DR: Compared the developed immunoassay with commercially available enzyme linked immunosorbent assay, the proposed method showed good precision, acceptable stability and reproducibility, indicating the immunosensor could be used for the sensitive, efficient and real-time detection of cortisol in real samples.
85 citations
••
TL;DR: A marked increase in the prevalence rates of allergic diseases in China (compared with earlier data) was evident, and the precise causes of this increase are warranted.
Abstract: Several studies conducted during the 1990s indicated that childhood allergic diseases were increasing worldwide, but more recent investigations in some Western countries have suggested that the trend is stabilizing or may even be reversing However, few data are available on the current status of allergic disease prevalence in Chinese children The aim of the present study was to investigate the prevalence rates of asthma, allergic rhinitis, and eczema in children of three major cities of China, to determine the status of allergic diseases among Chinese children generally, and to evaluate the prevalence of allergic diseases in children of different ages We conducted a cross-sectional survey between October 2008 and May 2009 in three major cities of China (Beijing, Chongqing, and Guangzhou) to evaluate the prevalence rates of childhood allergic diseases including asthma, allergic rhinitis, and eczema, using a questionnaire of the International Study of Asthma and Allergies in Childhood (ISAAC) group A total of 24,290 children aged 0-14 years were interviewed, using a multi-stage sampling method To acquire data on children aged 3-14 years, we visited schools and kindergartens To access children too young to attend school or kindergarten, we extended our survey to community health service centers Each questionnaire was completed by a parent or guardian of a child after an informed consent form was signed Of the 24,290 children in our study, 12,908 (5314%) were males and 11,382 (4686%) females; 10,372 (4270%) were from Beijing, 9,846 (4053%) from Chongqing, and 4,072 (1677%) from Guangzhou Our survey indicated that in Beijing, Chongqing, and Guangzhou, the prevalence rates of asthma were 315%, 745%, and 209%, respectively; the rates of allergic rhinitis were 1446%, 2042%, and 783%; and the rates of eczema were 2064%, 1002%, and 722% The prevalence of allergic diseases varied with age Asthma was relatively less common both in children aged under 2 years, and in those aged 9 years or more, in each of the three cities The prevalence of allergic rhinitis was also lower in children younger than 2 years The prevalence of eczema fell with age A marked increase in the prevalence rates of allergic diseases in China (compared with earlier data) was evident Further studies exploring the precise causes of this increase are warranted
85 citations
••
TL;DR: No nationwide studies have examined the associations between mortality risk and PM1 (PM with an aerodynamic diameter of <1 μm) due to the scarcity of monitoring data of PM1, but on the basis of newly released data, a nationwide study is warranted.
Abstract: No nationwide studies have examined the associations between mortality risk and PM1 (PM with an aerodynamic diameter of <1 μm) due to the scarcity of monitoring data of PM1. On the basis of newly r...
85 citations
••
TL;DR: Three cDNAs isolated from the human hookworm Necator americanus encoding a full-length GST protein belonging to a nematode-specific nu-class GST family exhibited low lipid peroxidase and glutathione-conjugating enzyme activities but high heme-binding capacities, and they may be involved in the detoxification and/or transport of heme.
Abstract: Hookworm glutathione S-transferases (GSTs) are critical for parasite blood feeding and survival and represent potential targets for vaccination. Three cDNAs, each encoding a full-length GST protein from the human hookworm Necator americanus (and designated Na-GST-1, Na-GST-2, and Na-GST-3, respectively) were isolated from cDNA based on their sequence similarity to Ac-GST-1, a GST from the dog hookworm Ancylostoma caninum. The open reading frames of the three N. americanus GSTs each contain 206 amino acids with 51% to 69% sequence identity between each other and Ac-GST-1. Sequence alignment with GSTs from other organisms shows that the three Na-GSTs belong to a nematode-specific nu-class GST family. All three Na-GSTs, when expressed in Pichia pastoris, exhibited low lipid peroxidase and glutathione-conjugating enzymatic activities but high heme-binding capacities, and they may be involved in the detoxification and/or transport of heme. In two separate vaccine trials, recombinant Na-GST-1 formulated with Alhydrogel elicited 32 and 39% reductions in adult hookworm burdens (P < 0.05) following N. americanus larval challenge relative to the results for a group immunized with Alhydrogel alone. In contrast, no protection was observed in vaccine trials with Na-GST-2 or Na-GST-3. On the basis of these and other preclinical data, Na-GST-1 is under possible consideration for further vaccine development.
85 citations
Authors
Showing all 16076 results
Name | H-index | Papers | Citations |
---|---|---|---|
Richard Peto | 183 | 683 | 231434 |
Barry M. Popkin | 157 | 751 | 90453 |
Jian Yang | 142 | 1818 | 111166 |
Edward C. Holmes | 138 | 824 | 85748 |
Jian Li | 133 | 2863 | 87131 |
Shaobin Wang | 126 | 872 | 52463 |
Elaine Holmes | 119 | 560 | 58975 |
Jian Liu | 117 | 2090 | 73156 |
Sherif R. Zaki | 107 | 417 | 40081 |
Jun Yang | 107 | 2090 | 55257 |
Nan Lin | 105 | 687 | 54545 |
Li Chen | 105 | 1732 | 55996 |
Ming Li | 103 | 1669 | 62672 |
George F. Gao | 102 | 793 | 82219 |
Tao Li | 102 | 2483 | 60947 |